The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers

Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed pr...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-04, Vol.24 (8), p.7293
Main Authors: Tang, Hiu, Kulkarni, Sanat, Peters, Christina, Eddison, Jasper, Al-Ani, Maryam, Madhusudan, Srinivasan
Format: Article
Language:English
Subjects:
BRCA
Cancer
Carcinoma, Ovarian Epithelial - drug therapy
Carcinoma, Ovarian Epithelial - genetics
Chemotherapy
DNA
DNA - therapeutic use
DNA repair
Female
Genetic aspects
Humans
Monosaccharides
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
PARPi
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Poly(ADP-ribose) Polymerases
Precision Medicine
precision oncology
Review
Sugars
synthetic lethality
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed precision oncology strategy has generated hope for patients. The clinical use of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA germ-line-deficient and/or platinum-sensitive epithelial ovarian cancers has improved survival. However, the emergence of resistance is an ongoing clinical challenge. Here, we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in epithelial ovarian cancers.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24087293